{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:02Z","timestamp":1792789022405,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ijrobp.2013.11.010","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T12:06:39Z","timestamp":1390392399000},"page":"892-898","source":"Crossref","is-referenced-by-count":190,"title":["Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib"],"prefix":"10.1016","volume":"88","author":[{"given":"Gregory N.","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Scheier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Doebele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie E.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2013.11.010_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib2","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/JCO.2011.39.9766","article-title":"Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer","volume":"30","author":"Kim","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib4","first-page":"S204","article-title":"Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)","volume":"7","author":"Riely","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib6","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib8","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/jco.2011.29.15_suppl.2501","article-title":"Progression-free survival from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer","volume":"29","author":"Camidge","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib9","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib11","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib14","first-page":"278","article-title":"Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence","volume":"100","author":"Hughes","year":"1986","journal-title":"Surgery"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I","article-title":"Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie","volume":"77","author":"Nordlinger","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1748-717X-6-34","article-title":"Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control","volume":"6","author":"Stinauer","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","article-title":"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7 Suppl. 3","key":"10.1016\/j.ijrobp.2013.11.010_bib18","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib19","unstructured":"Shaw AT, Kim DW, Nakagawa K, et\u00a0al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007). Presented at the European Society for Medical Oncology 37th Annual Meeting, September 28 -October 2, 2012, Vienna, Austria."},{"key":"10.1016\/j.ijrobp.2013.11.010_bib20","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JTO.0b013e31827e1f83","article-title":"Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors","volume":"8","author":"Yu","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib23","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/JTO.0b013e31827a892c","article-title":"Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer","volume":"8","author":"Browning","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2013.11.010_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cllc.2011.05.001","article-title":"Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer","volume":"13","author":"Lee","year":"2012","journal-title":"Clin Lung Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613033130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613033130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T18:34:16Z","timestamp":1565116456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301613033130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0360301613033130"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2013.11.010","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}